🧬 Drug Discovery • AI • Pain Management • Non-Opioid Analgesics

Scientists Use AI to Find a Pain Drug That Outperformed Morphine

📋 Insilico Medicine • ISM9528 • First-in-Class • Non-Opioid • Chronic Pain • 7 min read AI-designed pain drug ISM9528 outperformed morphine in preclinical studies — Insilico Medicine breakthrough in non-opioid pain management

AI-designed pain drug ISM9528 outperformed morphine in preclinical studies — Insilico Medicine breakthrough in non-opioid pain management

🧬 An AI-discovered non-opioid pain candidate has outperformed morphine in preclinical studies — potentially marking a paradigm shift in pain management.

🧬 The Breakthrough — An AI-Discovered Non-Opioid Painkiller

In the United States, scientists from Insilico Medicine have published the results of preclinical laboratory studies presenting a potential first-in-class, non-opioid pain drug developed using their proprietary artificial intelligence platform. The compound, designated ISM9528, targets a previously unexplored biological mechanism — not opioid receptors, but a fundamentally different molecular pathway.

The drug is administered orally, crosses the blood-brain barrier, and in preclinical models of surgical and neuropathic pain, small doses outperformed morphine within six hours of administration — while demonstrating a favorable safety profile.

🧬

First-in-Class

Novel non-opioid mechanism

⚡

Outperformed Morphine

At small doses in preclinical models

⏱️

12–18 Months

AI-accelerated development timeline

💡 Key Insight: “To see a non-opioid candidate outperform morphine in preclinical models is an unprecedented milestone, perhaps one of the most remarkable and unexpected results in our company’s history,” said Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine.

🌍 The Pain Crisis — A Global Unmet Medical Need

Despite the widespread availability of analgesics, pain management remains one of the most significant challenges in modern medicine. More than 20% of the global population suffers from chronic pain, particularly chronic neuropathic pain characterized by central sensitization.

The standard of care currently relies heavily on opioids and NSAIDs, which are limited by inadequate efficacy, gastrointestinal toxicity, and the serious risks of dependence and addiction. The opioid crisis continues to grow worldwide, creating an urgent need for novel, effective, non-addictive, brain-penetrant analgesics.

📊

>20% of Global Population

Suffer from chronic pain — a massive unmet medical need.

💊

Opioid Crisis

Current treatments carry serious risks of dependence and addiction.

💰

$100 Billion Market

Global pain management market projected to reach $100 billion by 2032.

🤖 How AI Discovered the New Pain Mechanism

The research team leveraged PandaOmics, Insilico’s AI engine for target identification, to analyze massive datasets of omics, textual, and multimodal data. This uncovered a new pain-related pattern — highlighting a novel target designated “Target Z” that had not been systematically linked to pain management before.

Subsequent bioinformatics analyses showed high expression of Target Z in pain-related cell types, strengthening confidence to advance into wet lab testing. Moving swiftly into in vivo validation, specialized mouse models demonstrated robust, dose-dependent pain management efficacy, with potential comparable or surpassing current solutions, including morphine.

1️⃣

Target Discovery

PandaOmics analyzed omics, textual, and multimodal data to uncover Target Z — a novel mechanism not previously linked to pain.

2️⃣

Target Validation

Bioinformatics confirmed high expression in pain-related cells; mouse models validated dose-dependent efficacy.

3️⃣

Drug Design

Chemistry42 generated and optimized ISM9528 with brain-penetrant properties and balanced safety/efficacy.

📌 Key Insight: “Target discovery for highly complex human mechanisms like chronic pain and migraine historically takes over a decade, but PandaOmics precisely mapped this pathway, driving us to our 31st PCC since 2021,” said Dr. Alex Zhavoronkov.

📊 Preclinical Data — Superior Efficacy and Safety

In preclinical studies, ISM9528 demonstrated a superior therapeutic profile compared to the standard of care:

Parameter	ISM9528	Comparator
Acute Post-Surgical Pain Model	Superior efficacy	Pregabalin
Neuropathic Pain (SNL Rat Model)	Comparable to Pregabalin	Pregabalin
Rapid Onset	0.5 hours	Standard comparators
Opioid Comparison	Outperformed morphine	Morphine
Safety Profile	Favorable, 44-panel safety screening	Opioid-related risks

💡 Key Finding: In the postsurgical acute pain model, ISM9528 demonstrated rapid-acting efficacy at 0.5 hours post-dosing, outperforming the equivalent dose of pregabalin.

🛡️ Safety Profile — A Favorable Risk-Benefit Balance

✅

Comprehensive Safety Screenings

ISM9528 passed 44-panel safety screenings across multiple in vitro and in vivo models.

🧬

High Selectivity

Highly selective for Target Z — minimizing off-target effects.

🩸

Brain-Penetrant

Excellent blood-brain barrier permeability with rapid systemic absorption.

⚡ AI-Accelerated Drug Discovery — From 4.5 Years to 12–18 Months

The development of ISM9528 highlights the transformative power of AI in drug discovery:

📉

Traditional Timeline

2.5–4.5 years from target discovery to preclinical candidate nomination.

🚀

AI-Accelerated Timeline

12–18 months — reduced by 60–70% using AI-powered platforms.

🧪

Efficiency

Only 60–200 molecules synthesized per program, compared to thousands traditionally.

💡 Key Insight: Since 2021, Insilico has nominated 31 preclinical candidates, with 13 already at the IND-approved or IND-cleared stage — validating the reproducibility and scale of their AI platform.

🔬 Next Steps — Toward Clinical Trials

The company is fast-tracking the program toward clinical trials in 2027. Next steps include:

🧪

GLP Tox Studies

GLP-compliant toxicology studies planned to support IND filing.

📋

IND Filing

Investigational New Drug application to enable human trials.

🧑‍⚕️

Phase I Trials

First-in-human trials planned for 2027 to evaluate safety and tolerability.

📌 Important: “We are fast-tracking this exciting program toward clinical trials in 2027, driven to deliver a medicine that will genuinely transform patient care,” said Dr. Carol Satler, Senior Vice President for Clinical Development at Insilico Medicine.

❓ Frequently Asked Questions

What is ISM9528?

ISM9528 is a potential first-in-class, non-opioid pain drug discovered and developed using AI by Insilico Medicine. It targets a previously unexplored mechanism (Target Z) and is administered orally.

How does ISM9528 compare to morphine?

In preclinical studies, ISM9528 outperformed morphine in models of surgical and neuropathic pain at small doses within six hours of administration, while demonstrating a favorable safety profile without opioid-related risks.

What is Target Z?

Target Z is a novel biological mechanism identified by Insilico’s AI platform PandaOmics. It had not been systematically linked to pain management before this discovery.

When will ISM9528 be available to patients?

The company is fast-tracking ISM9528 toward clinical trials in 2027. It remains an experimental compound and is not yet approved for use in humans.

How did AI help discover this drug?

Insilico used PandaOmics to identify the novel pain target and Chemistry42 to generate and optimize the drug molecule. This AI-powered approach reduced typical discovery timelines from 4.5 years to 12–18 months.

📚 References & Resources

⚠️ Medical Disclaimer

This content is for informational and educational purposes only. The research findings discussed are preliminary and based on preclinical studies. ISM9528 is an experimental compound that has not yet been tested in humans and is not currently available as a treatment. This information does not constitute medical advice. Always consult a qualified healthcare professional for personalized health guidance, especially if you have concerns about pain management or opioid use.

Dr. Tina Sugandh

All Author Posts

All Departments

Recently Viewed